奥氮平预防化疗所致恶心呕吐的疗效观察被引量：4

下载PDF

导出

摘要目的观察奥氮平预防化疗所致恶心呕吐的疗效。方法收集180例化疗患者,分为观察组和对照组,各90例。两组均在化疗前30 min给予静脉滴注昂丹司琼针8 mg+奥美拉唑针40 mg减轻胃肠道反应;观察组自化疗第1天开始早晚各口服奥氮平5 mg,连用5 d。观察两组患者恶心呕吐的发生情况及其他不良反应。结果观察组和对照组急性恶心呕吐的发生率分别为38.89%(35/90)和60.00%(54/90),两组差异有统计学意义(<0.05);观察组和对照组迟发性恶心呕吐的发生率分别为13.33%(12/90)和51.11%(46/90),两组差异有统计学意义(<0.05);两组食欲下降发生率差异有统计学意义(<0.05);其他两组差异均无统计学意义(均>0.05)。结论奥氮平对化疗患者预防恶心呕吐具有较好的疗效,尤其对迟发性恶心呕吐疗效更明显。

作者王师沈燕萍兰朋训王华英俞万钧

机构地区宁波市鄞州人民医院

出处《现代实用医学》 2016年第1期18-19,38,共3页 Modern Practical Medicine

关键词奥氮平化疗恶心呕吐

分类号 R730.5 [医药卫生—肿瘤]

引文网络
相关文献

参考文献12

1Wiser W, Berger A. Practical manage- merit of chemotherapy induced nausea and vomiting[J]. Oncology (Williston Park), 2005, 19(5):637-645.
2Hesketh PJ. Understanding the pathobi- ology of chemotherapy-induced nausea and vomiting: Providing a basis for thera- peutic progress [J]. Oncology (Williston Park), 2004, 18:9-14.
3Bymastcr F, Perry KW, Nelson DL, et al. Olanzapine: a basic science update[J]. Br J Psychiatry Suppl, 1999, 37:36-40.
4马剑,韩正祥.化疗引起的恶心呕吐机制研究进展及其对策[J].徐州医学院学报,2010,30(9):627-630. 被引量：53
5Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in caucer patients[J]. J Pain Symptom Manage, 2003, 25(5):485-488.
6Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Ontology Group study[J]. Cancer Invest, 2004, 22(3):383-388.
7Navafi RM, Einhom LH, Passik SD, et al. A phase II trial of olanzapine for the pre- vention of chemotherapy-induced nausea and vomiting: a Hoosier Oneology Group study[J]. Support Care Cancer, 2005, 13 (7):529-534.
8Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomit- ing: a randomized phase III trial[J]. J Sup- port Oncol, 2011, 9(5):188-195.
9Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemothera- py-induced nausea and vomiting in pati- ents receiving highly emetogenic chemo- therapy[J]. Support Care Cancer, 2013, 21 (6):1655-1663.
10Tan L, Liu J, Liu X, et al. Clinical research of Olanzapine for prevention of chemo- therapy-induced nausea and vomiting[J]. J Exp Clin Cancer Res, 2009, 28:131.

二级参考文献56

1张晓静,张频.肿瘤化疗所致恶心呕吐的发生机制和药物治疗的研究进展[J].癌症进展,2006,4(4):348-354. 被引量：129
2金在久.桔梗的化学成分及药理和临床研究进展[J].时珍国医国药,2007,18(2):506-509. 被引量：78
3陈文彬.诊断学[M].7版.北京:人民卫生出版社,2008:35-37.
4Jordan K,Kasper C,Schmoll HJ.Chemotherapy-induced nausea and vomiting:current and new standards in the antiemetic prophylaxis and treatment[J].Eur J Cancer,2005,41(2):199-205.
5Morrow GR,Roscoe JA,Kirshner JJ,et al.Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics[J].Support Care Cancer,1998,6(3):244-247.
6Abrahamsson H,Thorén P.Vomiting and reflex vagal relaxation of the stomach elicited from heart receptors in the cat[J].Acta Physiol Scand,1973,88(4):433-439.
7Fukui H,Yamamoto M,Sato S.Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs[J].Jpn J Pharmacol,1992,59(2):221-226.
8Racké K,Reimann A,Schwrer H,et al.Regulation of 5-HT release from enterochromaffin cells[J].Behav Brain Res,1996,73(1-2):83-87.
9Higgins GA,Kilpatrick GJ,Bunce KT,et al.5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret[J].Br J Pharmacol,1989,97(1):247-255.
10Carpenter DO,Briggs DB,Strominger N.Peptide-induced emesis in dogs[J].Behav Brain Res,1984,11(3):277-281.